CTLA4 and Miyoshi myopathy: Notably, anti-PD-1 seems to be associated with a higher efficacy than anti-CTLA-4 in MM, as it was demonstrated in a cohort of 44 first-line-treated patients with unresectable and/or metastatic MM.